OxDX Raises £2.6M Pre-Seed Funding to Develop AI Powered Rapid Diagnostic Technology

OxDX, a University of Oxford spin out building instant pathogen tests using super-resolution microscopy and machine learning, has raised £2.6m in pre-seed funding for its AI powered diagnostic technology that can recognise and identify specific species and strains of viruses(1,2,) bacteria and other pathogens within a sample in seconds. The initial funding is co-led by IQ Capital and Ahren Innovation Capital with participation from Science Creates Ventures, and will be used to expand the team and further validate the technology with development partners.

The OxDX technology uses novel universal labelling technology in combination with machine learning analysis in a neural network to identify the specific pathogens causing infection in just a few seconds. The team has demonstrated the ability to identify respiratory viruses in clinical samples and, in the case of COVID-19 and influenza viruses, directly identify the strain. The Company aims to develop an ultra-fast analysis platform capable of rapidly scaling to many diseases via simple software updates improving the cost and access to infectious disease diagnostics worldwide.

Alex Batchelor, Chief Executive Officer of OxDX, said: "Our ability to take a sample from someone with an unknown infection and answer the open question 'what do they have?' within a minute is a gamechanger for infection diagnosis and treatment. We'll start with respiratory viruses and expand from there. In parallel, we'll be simplifying the workflow to move the test from the lab to point of care, which will represent a step change in the availability and cost of infectious disease diagnostics worldwide."

Ed Stacey, Managing Partner at IQ Capital Partners, added: "The potential of OxDX's technology to identify diseases 'while you wait,' and roll out tests for new pathogens with just a software update is going to revolutionise diagnostics and patient treatment. This incredible team have already achieved an enormous amount and I’m looking forward to seeing the impact they have on the field of infectious disease diagnostics."

Dr Joanna Green, Principal at Ahren Innovation Capital, commented: "We look forward to working with the OxDX team to achieve the full potential of their technology, operating at the intersection of machine learning and microscopy, applied to diagnostics. This type of transformative technology can have a huge positive impact on the world."

For further information, please visit:
https://www.oxdx.com

About OxDX Ltd

OxDX is a rapid pathogen detection company, a spin out from the University of Oxford, which combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. Our primary goal is to develop rapid diagnostics tools that enable clinicians to ask widely open questions about the causes of infection.

About IQ Capital Partners

IQ Capital is the leading deeptech venture capital firm. Based in London and Cambridge, IQ Capital invests in early-stage deeptech businesses using hard-to-replicate technology in massive global markets - across sectors including software, hardware, materials, health tech and life sciences.

IQ Capital's 50+ portfolio companies are visionaries and address some of the largest problems in the world to dominate their respective markets on a global scale and grow rapidly to become sector leaders. Our initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through our Growth Fund.

The IQ Capital team has achieved over 20 exits, to companies including M&A to Apple, Google, Facebook, Oracle and several IPOs. IQ Capital has led over 30 investments in the last three years in outstanding companies including Thought Machine, Privitar, FNA, Paragraf, causaLens, Neurovalens, Concirrus, Fluidic Analytics, CybSafe, Nyobolt.

About Ahren Innovation Capital

Ahren Innovation Capital is an investment institution that supports transformational companies at the cutting edge of deep science and deep tech. A group of highly diverse, creative and original thinkers leading their domains, Ahren Innovation Capital believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology. With a philosophy espousing the importance of relationships and trust, Ahren Innovation Capital provides long-term capital and support to exceptional founders and teams, empowering them to achieve the unimaginable.

About Science Creates Ventures

Science Creates Ventures is a Bristol-based venture capital firm. Our EIS Fund 1 offers investment into early-stage deep tech companies, focusing on technologies that have the potential to improve healthcare, quality of life, and the environment around us. We're supported and backed by successful entrepreneurs behind multiple tech and deep tech exits in the South-West.

1. Virus detection and identification in minutes using single-particle imaging and deep learning, medRxiv https://www.medrxiv.org/content/10.1101/2020.10.13.20212035v3
2. Rapid functionalisation and detection of viruses via a novel Ca 2+-mediated virus-DNA interaction, Scientific Reports Nature Research https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838052/

Most Popular Now

Collective Intelligence can Help Reduce …

An estimated 250,000 people die from preventable medical errors in the U.S. each year. Many of these errors originate during the diagnostic process. A powerful way to increase diagnostic accuracy...

New Study Suggests ECG-AI can Detect Car…

Artificial intelligence (AI) from patient electrocardiograms (ECGs) may be an innovative solution to enhance heart disease risk assessment. Atherosclerotic cardiovascular disease - arteries narrowed or blocked by the accumulation of...

Software Created from 'Building Blo…

New 'building-block' approaches to the creation of digital tools which include data and artificial intelligence (AI) could play a key role in improving the running of hospital wards and disease...

How could Technology Better Support Pati…

The NHS exists to serve patients. But more could be done to make their experience a key focus when it comes to technology adoption, senior NHS delegates told a recent...

"Showtime" for Digital Health …

13 - 16 November 2023, Düsseldorf, Germany. A hundred start-ups and more than 120 high-calibre professional speakers: These are just the "naked" facts which this year's MEDICA CONNECTED HEALTHCARE FORUM will...

Artificial Intelligence: Unexpected Resu…

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics...

Philips Program Developing AI-Powered Ul…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received a second round of funding from the Bill & Melinda Gates Foundation to...

CGM Continues to Drive Digitization in H…

CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023. CGM supports physicians...

Wolverhampton's New 10-Year EPR Dea…

The Royal Wolverhampton NHS Trust (RWT) has just signed a 10-year contract with System C for an integrated electronic patient record (EPR) system, which will replace the trust's in-house built...

Printed Robots with Bones, Ligaments, an…

3D printing is advancing rapidly, and the range of materials that can be used has expanded considerably. While the technology was previously limited to fast-curing plastics, it has now been...

Orchestrating the New World of AI in Hea…

Orion Health's UK and Ireland Customer Conference 2023 focused on the future potential and immediate, practical application of AI to healthcare - and gave delegates a first look at the...

Researchers Take New AI Approach to Anal…

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue...